Rock Springs Capital Management LP Grows Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Rock Springs Capital Management LP lifted its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 463,088 shares of the company’s stock after acquiring an additional 4,000 shares during the period. Rock Springs Capital Management LP owned approximately 3.09% of Jasper Therapeutics worth $9,901,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Wells Fargo & Company MN raised its position in Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at about $223,000. Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at about $251,000. Barclays PLC lifted its position in Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after acquiring an additional 12,308 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after acquiring an additional 11,567 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Up 1.3 %

Shares of NASDAQ JSPR opened at $3.97 on Monday. Jasper Therapeutics, Inc. has a 12-month low of $3.13 and a 12-month high of $26.84. The company has a market cap of $59.64 million, a price-to-earnings ratio of -0.84 and a beta of 2.55. The stock’s 50 day simple moving average is $4.97 and its 200 day simple moving average is $12.78.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). As a group, equities analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. UBS Group assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 price target on the stock. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.